Compare Nuwellis Inc (NUWE) vs USA Rare Earth Inc. Class A Common Stock (USAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs USA Rare Earth Inc. Class A Common Stock — how do they compare? Nuwellis Inc trades at $0.55 (market cap $2.00M), while USA Rare Earth Inc. Class A Common Stock trades at $10.1 (market cap $4.23B). The key difference: USA Rare Earth Inc. Class A Common Stock is far larger — about 2115× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (172,259 versus 13,677,660). Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 27 Days and USA Rare Earth Inc. Class A Common Stock for 0 Days on average.
| NUWE | USAR | |
|---|---|---|
Market Cap | $2.00M | $4.23B |
Volume | 172,259 | 13,677,660 |
Sector | Health | Basic Materials |
52-Week High | $146.65 | $33.68 |
52-Week Low | $0.53 | $10.32 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | -$1.72M | $2.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.621, down 7.35% today, with a bearish technical signal despite oversold RSI readings. The company shows revenue growth with 2026 revenue reaching $9M, but continues to post significant losses with a -125.63% net income margin. Recent positive developments include strong Aquadex console adoption and expanded pediatric footprint, though cash flow remains negative requiring ongoing financing.
The outlook remains challenging with persistent losses and negative cash flow offset by promising commercial momentum. Investment opportunity hinges on the company's ability to achieve profitability while risks include execution challenges and dependence on financing. Analyst sentiment is mixed with equal buy/hold ratings reflecting the high-risk, high-reward nature of this medical technology stock.
USA Rare Earth (USAR) trades at $11.265, down 4.7% today and near its 52-week low, reflecting persistent sector pressure. The company shows severe financial strain with a net income margin of -2,159.3% and negative cash flow from operations, though analyst consensus remains unanimously bullish with a $34.57 price target. Recent news highlights strategic investments in a $1.2 billion South Carolina facility and a $2.8 billion Brazil acquisition to build a mine-to-magnet supply chain, positioning it for long-term growth amid U.S. critical mineral initiatives.
The stock presents high risk due to extreme losses and cash burn but offers speculative upside if government funding and project milestones materialize. Key risks include execution challenges, reliance on future financing, and sector volatility. Investors should weigh the bullish analyst outlook against the company's current financial instability and macroeconomic headwinds affecting rare earth markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About USA Rare Earth Inc. Class A Common Stock
USA Rare Earth is building an integrated rare earth and permanent magnet supply chain spanning mining, metal and alloy production, and magnet manufacturing, with assets including the Round Top heavy rare earth deposit in Texas, a magnet manufacturing facility in Stillwater, Oklahoma, and metal-and-alloy producer Less Common Metals.
Read more on USAR →
